Read Company Summaries (pdf)
Airbase Therapeutics
AirBase Therapeutics develops alkaline formulations of FDA-approved inhaled medications that have superior efficacy in the acidic asthmatic airway.
| Principals |
Advisors |
Facilitator |
- John Hunt
- Christopher Lauderback
|
- Jay Brennan
- David Walsh |
- Deborah Van Eersel |
Healing Orthopaedic Technologies (HOT)
HOT has developed breakthrough technologies for soft tissue regeneration, allowing it to address tremendous unmet needs in the repair of musculoskeletal soft tissue injuries of the knee and shoulder.
| Principals |
Advisors |
Facilitator |
- Joseph Reilly
- Cato Laurencin
- Lakshmi Nair
- Mark Aronson
|
- David Hunt
- George Golumbeski
- Warren Estey
|
- Elizabeth Roark |
HemoSonics | Website
HemoSonics is developing novel diagnostic instruments to rapidly quantify blood clotting and bleeding disorders. Unregulated blood clotting and bleeding (ie, unregulated hemostatic functions) represent the leading cause of mortality in the developed world..
| Principals |
Advisors |
Facilitator |
- Bill Walker
- Francesco Viola
- Michael Lawrence |
- Fred Hutchison
- Jim Millar
|
- Lianne Landers |
Phthisis Diagnostics | Website
Phthisis (pronounced ty-sis) is a molecular diagnostic company that develops cutting edge diagnostic reagents for the detection of infectious diseases.
| Principals |
Advisors |
Facilitator |
- Eric Houpt
- Crystal Icenhour
|
- Gerry Brunk
- Keith Barritt
- Steve Sinnenberg |
- Uday Gupta |
PocketMed | Website
PocketMed is a medical software company that has emerged as a leader in mobile charge capture solutions for healthcare practitioners. PocketBilling© allows physicians to capture charges at the point of care, thereby shortening billing cycles and increasing their revenues.
| Principals |
Advisors |
Facilitator |
-Scott Strayer
|
- David Peyton
- Khurrum Malik
|
- David Jones |
Tau Therapeutics | Website
Tau is an oncology company focused on calcium T-channel therapy agents that are designed to halt the growth of tumors. The discovery of a potent pathway to block cell growth has led to a cytostatic checkpoint therapy that offers lower side-effects, neuropathic pain relief, ease of use in the form of a daily pill and economical manufacturing costs.
| Principals |
Advisors |
Facilitator |
- Lloyd Gray
- Tim Macdonald
- Andrew Krouse
|
- Greg Giamittorio
- John Skeele
- Paul Sartori
|
- David Chen |
< Back to T100
|
